The prognosis for glioblastoma multiforme (GBM) is extremely poor. Identification of molecules whose targeting may eliminate GBM cells and/or sensitize GBM responses to cytotoxic and targeted agents is therefore urgently needed. CD44 is a major cell surface receptor for hyaluronan (HA) and a cancer stem cell marker, and has been implicated in cancer progression. However, little is known about its contributions to GBM progression and to the responses of GBM cells to chemo- and targeted therapies and about the major downstream signaling pathway that mediates the pro-tumor effect of CD44. We show that CD44 is up regulated in malignant gliomas and that its depletion blocks GBM growth and sensitizes GBM cells to cytotoxic drugs in vivo. We first demonstrate that CD44 antagonists display potent anti-GBM efficacy in mouse models and that CD44 functions upstream of mammalian Hippo signaling pathway. Furthermore, CD44 promotes GBM cell resistance to reactive oxygen species- and cytotoxic agent-induced stress and apoptosis by attenuating activation of the Hippo pathway kinases MST1/2 and Lats1/2. We also show that CD44 enhances the growth signals derived from ErbB and c-Met receptor tyrosine kinases (RTKs). Based on these results, we hypothesize that CD44 antagonists inhibit GBM progression and sensitize GBM responses to chemo- and targeted therapies by inhibiting GBM cell survival through enhancing activation of the Hippo signaling pathway and inhibiting the growth signals derived from ErbB/c-Met RTKs. We further hypothesize that CD44 is a prime target for GBM therapy and its antagonists are efficacious when used as single agents and/or combination with chemotherapeutic agents and pharmacological inhibitors of erbB and c-Met RTKs in the GBM mouse models.
Three specific aims are proposed.
Aim 1 is to establish that CD44 antagonists, a variety of soluble CD44-Fc fusion proteins, display anti- glioma activity, sensitize GBM response to chemo- and targeted therapies in vivo.
Aim 2 is to establish that the chemosensitizing effect of CD44 antagonists in vivo is achieved by enhancing activation of Hippo signaling pathway. Finally, aim 3 is to establish that hsCD44-Fc fusion proteins achieve their anti-glioma effect and sensitize GBM response to the targeted therapies, at least partially, through inhibiting activities of erbB and c-Met RTKs. The results from proposed experiments will establish CD44 as a prime therapeutic target for GBM and demonstrate potent therapeutic efficacies of the newly developed CD44 antagonists as single agents and/or in combinations with chemo- and other targeted therapies in preclinical GBM models. These results may lead to better clinical outcome and longer lasting clinical benefit for GBM patients in the future. Therefore, this proposal has high biological and clinical relevance and significance, and translational potential.
Glioblastoma multiforme (GBM) is the most aggressive brain tumor that, by virtue of its resistance to chemo- and radiotherapy, is incurable, and therefore identification of molecules whose targeting will eliminate GBM cells and/or sensitize the responses of glioblastoma cells to cytotoxic and other established targeted agents is urgently needed. This proposal is to establish that CD44 is a prime therapeutic target for GBM and its antagonists, soluble human CD44-Fc fusion proteins, are efficacious when used as single agents and/or in combinations with chemotherapeutic agents and existing pharmacological inhibitors of erbB and c-Met receptor tyrosine kinases in the mouse GBM models, which may lead to development of novel agents and combination treatments to achieve better clinical outcome and longer lasting clinical benefit for GBM patients in the future. Therefore, this proposal has high biological and clinical relevance and significance, and translational potential.
|Xu, Yin; Wang, Kaiqiang; Yu, Qin (2016) FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases. Oncotarget :|
|Brunckhorst, Melissa K; Xu, Yin; Lu, Rong et al. (2014) Angiopoietins promote ovarian cancer progression by establishing a procancer microenvironment. Am J Pathol 184:2285-96|
|Gong, Yixuan; Scott, Evita; Lu, Rong et al. (2013) TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression. PLoS One 8:e77366|
|Brunckhorst, Melissa K; Lerner, Dimitry; Wang, Shaomeng et al. (2012) AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer. Cancer Biol Ther 13:804-11|
|Murray, Lucas B; Lau, Ying-Ka Ingar; Yu, Qin (2012) Merlin is a negative regulator of human melanoma growth. PLoS One 7:e43295|
|Stamenkovic, Ivan; Yu, Qin (2010) Merlin, a ""magic"" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci 11:471-84|
|Xu, Yin; Stamenkovic, Ivan; Yu, Qin (2010) CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res 70:2455-64|
|Stamenkovic, Ivan; Yu, Qin (2009) Shedding light on proteolytic cleavage of CD44: the responsible sheddase and functional significance of shedding. J Invest Dermatol 129:1321-4|